Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06386146 · ClinicalTrials.gov registry record · Phase 1
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
A Phase 1 study of Solid Tumors, sponsored by Jacobio Pharmaceuticals Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 13
- Study locations
NCT06386146: Recruiting Phase 1 study of Solid Tumors, sponsored by Jacobio Pharmaceuticals Co..
NCT06386146 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 144 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (49% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06386146, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Jacobio Pharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Primary Outcome
Number and proportion of participants who experience at least one dose limiting toxicity (DLT)
Conditions Studied
Interventions
- DRUG JAB-30355
Study Locations (13)
Beijing Municipality
- Research Site - Beijing
- Research Site - Beijing
- Research Site - Beijing
Ohio
- Research site - Canton
- Research site - Cleveland
Colorado
- Research Site - Denver
Florida
- Research site - Lake Mary
Missouri
- Research site - St Louis
Tennessee
- Research Site - Nashville
Texas
- Research site - Houston
Guangdong
- Research Site - Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT06386146 shows while recruiting
NCT06386146 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JAB-30355 is the first listed.
NCT06386146 lists 13 locations in 10 states (Beijing Municipality, Ohio, Colorado).
Frequently Asked Questions
What is clinical trial NCT06386146 about?
NCT06386146 is a clinical study titled "JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation". This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
What is the current status of trial NCT06386146?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-07-24. Estimated completion is 2027-07.
What conditions does trial NCT06386146 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06386146?
The interventions under investigation include: JAB-30355 (DRUG).
Who is sponsoring clinical trial NCT06386146?
This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06386146 being conducted?
This trial has 13 study locations across Colorado, Florida, Missouri, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06386146's enrollment target sits among peer trials
144 42nd of 125 higher than 83 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI